NovoCure: FDA Approval for Optune Pax Triggers Fundamental Reevaluation Situation - H.C. Wainwright Sees Additional 265% Growth Potential
Reading Time: 3 minutes
NovoCure: FDA Approval for Optune Pax Triggers Fundamental Reevaluation Situation - H.C. Wainwright Sees Additional {[265% Growth Potential]} NovoCure (NVCR) is a biotech company specialized in the oncology sector. The core business of the company is the development and commercialization of the so-called Tumor Treating Fields (TTFields). These are alternating electric fields that specifically disrupt the division of cancer cells (mitosis), leading to cell death or slowing tumor growth, without significantly harming healthy tissue. NovoCure has...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
